Characteristics of patients who underwent an autologous SCT in first remission (AUTO1) or for relapsed/refractory lymphoma (AUTO2), with or without rituximab
| Characteristic . | AUTO1 no rituximab (n = 29) . | AUTO1 with rituximab (n = 21) . | AUTO2 no rituximab (n = 17) . | AUTO2 with rituximab (n = 19) . |
|---|---|---|---|---|
| Median age, y (range) | 57 (42-66) | 56 (38-73) | 57 (42-65) | 63 (45-76) |
| Male, n (%) | 26 (90) | 18 (86) | 14 (82) | 15 (79) |
| Female, n (%) | 3 (10) | 3 (14) | 3 (18) | 4 (21) |
| Median time from initial diagnosis, mo (range) | 7 (4-63) | 8 (6-55) | 27 (5-84) | 26 (7-65) |
| Median no. of prior chemotherapy regimens (range) | 1 | 1 | 2 (2-3) | 2 (2-4) |
| Performance status at least 1, n (%) | 15 (52) | 8 of 18 (44) | 9 (53) | 6 of 14 (43) |
| Stage 3 or 4, n (%) | 28 (97) | 18 (86) | 15 (88) | 18 (95) |
| Prior B symptoms, n (%) | 6 (21) | 8 (38) | 4 (24) | 4 (21) |
| Prior GI involvement, n (%) | 13 (45) | 8 (38) | 3 (18) | 9 (47) |
| Prior blood involvement, n (%) | 1 (3) | 7 (33)* | 2 (12) | 5 (26) |
| Blastic morphology, n (%) | 2 (7) | 3 (14) | 1 (6) | 1 (5) |
| β2-microglobulin 3 mg/L or greater, n (%) | 6 of 24 (25) | 6 of 20 (30) | 1 of 13 (8) | 8 of 17 (47)† |
| Elevated LDH, n (%) | 5 (17) | 2 (10) | 6 (65) | 5 (26) |
| PET/Gallium positive pre-SCT | 0 of 14 (0) | 1 of 20 (5) | 1 of 4 (25) | 5 of 17 (29) |
| Bone marrow stem cell source, n (%) | 5 (17) | 1 (5) | 4 (24) | 1 (5) |
| Chemosensitive disease at transplantation, n (%) | 29 (100) | 21 (100) | 15 (88) | 16 (84) |
| CR/CRu at SCT, n (%) | 11 (38) | 12 (57) | 10 (59) | 15 (79) |
| PR at SCT n (%) | 18 (62) | 9 (43) | 5 (29) | 1 (5) |
| Refractory disease at SCT, n (%) | 0 (0) | 0 (0) | 2 (12) | 3 (16) |
| MIPI low risk, n (%) | 10 of 27 (37) | 6 of 13 (46) | 4 (57) | 3 of 8 (38) |
| MIPI intermediate risk, n (%) | 10 of 27 (37) | 3 of 13 (23) | 1 (14) | 1 of 8 (13) |
| MIPI high risk, n (%) | 7 of 27 (26) | 4 of 13 (31) | 2 (29) | 4 of 8 (50) |
| HSCT-CI less than 3, n (%) | 17 (59) | 11 (52) | 11 (65) | 7 (37) |
| HSCT-CI 3 or greater, n (%) | 12 (41) | 10 (48) | 6 (35) | 12 (63) |
| Characteristic . | AUTO1 no rituximab (n = 29) . | AUTO1 with rituximab (n = 21) . | AUTO2 no rituximab (n = 17) . | AUTO2 with rituximab (n = 19) . |
|---|---|---|---|---|
| Median age, y (range) | 57 (42-66) | 56 (38-73) | 57 (42-65) | 63 (45-76) |
| Male, n (%) | 26 (90) | 18 (86) | 14 (82) | 15 (79) |
| Female, n (%) | 3 (10) | 3 (14) | 3 (18) | 4 (21) |
| Median time from initial diagnosis, mo (range) | 7 (4-63) | 8 (6-55) | 27 (5-84) | 26 (7-65) |
| Median no. of prior chemotherapy regimens (range) | 1 | 1 | 2 (2-3) | 2 (2-4) |
| Performance status at least 1, n (%) | 15 (52) | 8 of 18 (44) | 9 (53) | 6 of 14 (43) |
| Stage 3 or 4, n (%) | 28 (97) | 18 (86) | 15 (88) | 18 (95) |
| Prior B symptoms, n (%) | 6 (21) | 8 (38) | 4 (24) | 4 (21) |
| Prior GI involvement, n (%) | 13 (45) | 8 (38) | 3 (18) | 9 (47) |
| Prior blood involvement, n (%) | 1 (3) | 7 (33)* | 2 (12) | 5 (26) |
| Blastic morphology, n (%) | 2 (7) | 3 (14) | 1 (6) | 1 (5) |
| β2-microglobulin 3 mg/L or greater, n (%) | 6 of 24 (25) | 6 of 20 (30) | 1 of 13 (8) | 8 of 17 (47)† |
| Elevated LDH, n (%) | 5 (17) | 2 (10) | 6 (65) | 5 (26) |
| PET/Gallium positive pre-SCT | 0 of 14 (0) | 1 of 20 (5) | 1 of 4 (25) | 5 of 17 (29) |
| Bone marrow stem cell source, n (%) | 5 (17) | 1 (5) | 4 (24) | 1 (5) |
| Chemosensitive disease at transplantation, n (%) | 29 (100) | 21 (100) | 15 (88) | 16 (84) |
| CR/CRu at SCT, n (%) | 11 (38) | 12 (57) | 10 (59) | 15 (79) |
| PR at SCT n (%) | 18 (62) | 9 (43) | 5 (29) | 1 (5) |
| Refractory disease at SCT, n (%) | 0 (0) | 0 (0) | 2 (12) | 3 (16) |
| MIPI low risk, n (%) | 10 of 27 (37) | 6 of 13 (46) | 4 (57) | 3 of 8 (38) |
| MIPI intermediate risk, n (%) | 10 of 27 (37) | 3 of 13 (23) | 1 (14) | 1 of 8 (13) |
| MIPI high risk, n (%) | 7 of 27 (26) | 4 of 13 (31) | 2 (29) | 4 of 8 (50) |
| HSCT-CI less than 3, n (%) | 17 (59) | 11 (52) | 11 (65) | 7 (37) |
| HSCT-CI 3 or greater, n (%) | 12 (41) | 10 (48) | 6 (35) | 12 (63) |
GI indicates gastrointestinal; LDH, lactate dehydrogenase; CR, complete response; CRu, unconfirmed CR; PR, partial response; MIPI, Mantle Cell International Prognostic Index; and HSCT-CI, Hematopoietic Stem Cell Transplantation-Comorbidity Index.
P < .05 comparing AUTO1 with or without rituximab.
P < .05 comparing AUTO2 with or without rituximab.